Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
cancer
3
×
europe blog main
3
×
europe top stories
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
accent therapeutics
aducanumab
alzheimer's disease
amblyotech
arena pharmaceuticals
asklepios biopharmaceutical
avapritinib
bioeurope
What
fda
3
×
cancer
drug
medicines
activity
address
approval
approvals
approves
bio
biogen
blueprint
carries
certain
clamped
covid
delays
designed
developing
economic
eisai
fast
flags
genetic
higher
incidence
including
ipo
isn’t
latest
lorcaserin
loss
lot
market
marketing
medicine
new
oric’s
pass
patients
Language
unset
Current search:
fda
×
" europe blog main "
×
cancer
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks